The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120

Vaccine

Volumn 28, Issue 2, 2009, Pages 352-360

  Hioe, Catarina E ^a,b   Visciano, Maria Luisa ^a   Kumar, Rajnish ^a   Liu, Jianping ^a   Mack, Ethan A ^a   Simon, Rachel E ^a   Levy, David N ^c   Tuen, Michael ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

Antibody response; HIV 1; Immune complex vaccine

Indexed keywords

ANTIGEN; CD4 ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS 1 ENVELOPE GP120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; EPITOPES; FEMALE; HIV ENVELOPE PROTEIN GP120; MICE; MICE, INBRED BALB C;

EID: 70649105392     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.040     Document Type: Article

References (46)

1. Visciano M.L., Tuen M., Gorny M.K., and Hioe C.E. In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 372 2 (2008) 409-420
2. Visciano M.L., Tuen M., Chen P.D., and Hioe C.E. Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect Agent Cancer 3 (2008) 11
3. Liao H.X., Alam S.M., Mascola J.R., Robinson J., Ma B., Montefiori D.C., et al. Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J Virol 78 10 (2004) 5270-5278
4. McCluskie M.J., Wen Y.M., Di Q., and Davis H.L. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 11 4 (1998) 245-252
5. Xu D.Z., Zhao K., Guo L.M., Li L.J., Xie Q., Ren H., et al. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3 7 (2008) e2565
6. Wen Y.M. Antigen-antibody immunogenic complex: promising novel vaccines for microbial persistent infections. Expert Opin Biol Ther 9 3 (2009) 285-291
7. Ivan J., Velhner M., Ursu K., German P., Mato T., Dren C.N., et al. Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can J Vet Res 69 2 (2005) 135-142
8. Alber D.G., Killington R.A., and Stokes A. Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d)) and C3H (H-2K(k)) mice. Vaccine 19 7-8 (2000) 895-901
9. Roic B., Cajavec S., Ergotic N., Lipej Z., Madic J., Lojkic M., et al. Immune complex-based vaccine for pig protection against parvovirus. J Vet Med B: Infect Dis Vet Public Health 53 1 (2006) 17-23
10. Rawool D.B., Bitsaktsis C., Li Y., Gosselin D.R., Lin Y., Kurkure N.V., et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180 8 (2008) 5548-5557
11. Corradin G., and Engers H.D. Inhibition of antigen-induced T-cell clone proliferation by antigen-specific antibodies. Nature 308 5959 (1984) 547-548
12. Simitsek P.D., Campbell D.G., Lanzavecchia A., Fairweather N., and Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med 181 6 (1995) 1957-1963
13. Manca F., Fenoglio D., Kunkl A., Cambiaggi C., Sasso M., and Celada F. Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. A possible influence of paratope specificity on the mode of antigen processing. J Immunol 140 9 (1988) 2893-2898
14. Williams J.G., Tomer K.B., Hioe C.E., Zolla-Pazner S., and Norris P.J. The antigenic determinants on HIV p24 for CD4+ T cell inhibiting antibodies as determined by limited proteolysis, chemical modification, and mass spectrometry. J Am Soc Mass Spectrom 17 11 (2006) 1560-1569
15. Chien Jr. P.C., Cohen S., Tuen M., Arthos J., Chen P.D., Patel S., et al. Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J Virol 78 14 (2004) 7645-7652
16. Tuen M., Visciano M.L., Chien Jr. P.C., Cohen S., Chen P.D., Robinson J., et al. Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur J Immunol 35 9 (2005) 2541-2551
17. Bouige P., Iscaki S., Cosson A., and Pillot J. Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. FEMS Immunol Med Microbiol 13 1 (1996) 71-79
18. Oli M.W., Rhodin N., McArthur W.P., and Brady L.J. Redirecting the humoral immune response against Streptococcus mutans antigen P1 with monoclonal antibodies. Infect Immun 72 12 (2004) 6951-6960
19. Isoda R., Robinette R.A., Pinder T.L., McArthur W.P., and Brady L.J. Basis of beneficial immunomodulation by monoclonal antibodies against Streptococcus mutans adhesin P1. FEMS Immunol Med Microbiol 51 1 (2007) 102-111
20. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4 3 (2004) 199-210
21. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24 (2006) 739-769
22. DeVico A.L. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. Curr HIV Res 5 6 (2007) 561-571
23. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80 5 (2006) 2515-2528
24. Blish C.A., Dogan O.C., Derby N.R., Nguyen M.A., Chohan B., Richardson B.A., et al. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol 82 24 (2008) 12094-12103
25. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 82 23 (2008) 11651-11668
26. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83 2 (2009) 757-769
27. Li Y., Svehla K., Louder M.K., Wycuff D., Phogat S., Tang M., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83 2 (2009) 1045-1059
28. Gelderblom H.C., Vatakis D.N., Burke S.A., Lawrie S.D., Bristol G.C., and Levy D.N. Viral complementation allows HIV-1 replication without integration. Retrovirology 5 (2008) 60
29. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 68 12 (1994) 8350-8364
30. Pinter A., Honnen W.J., Racho M.E., and Tilley S.A. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates. AIDS Res Hum Retrov 9 10 (1993) 985-996
31. Lusso P., Earl P.L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., et al. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79 11 (2005) 6957-6968
32. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., and Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol 80 14 (2006) 7127-7135
33. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., et al. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82 2 (2008) 638-651
34. Getahun A., and Heyman B. How antibodies act as natural adjuvants. Immunol Lett 104 1-2 (2006) 38-45
35. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79 16 (2005) 10108-10125
36. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14 3-4 (2005) 69-72
37. Cardozo T., Kimura T., Philpott S., Weiser B., Burger H., and Zolla-Pazner S. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retrov 23 3 (2007) 415-426
38. Cardozo T., Swetnam J., Pinter A., Krachmarov C., Nadas A., Almond D., et al. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res Hum Retrov 25 4 (2009) 441-450
39. Karwowska S., Gorny M.K., Buchbinder A., Gianakakos V., Williams C., Fuerst T., et al. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retrov 8 6 (1992) 1099-1106
40. Raja A., Venturi M., Kwong P., and Sodroski J. CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 77 1 (2003) 713-718
41. Hioe C.E., Tuen M., Chien Jr. P.C., Jones G., Ratto-Kim S., Norris P.J., et al. Inhibition of human immunodeficiency virus type 1 gp120 presentation to CD4 T cells by antibodies specific for the CD4 binding domain of gp120. J Virol 75 22 (2001) 10950-10957
42. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420 6916 (2002) 678-682
43. Labrijn A.F., Poignard P., Raja A., Zwick M.B., Delgado K., Franti M., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77 19 (2003) 10557-10565
44. Moore J.P., and Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J Virol 70 3 (1996) 1863-1872
45. Ratcliffe A., and Stanworth D.R. The localization of the binding site(s) on human IgG1 for the Fc receptors on homologous monocytes and heterologous mouse macrophages. Immunology 50 1 (1983) 93-100
46. Ratcliffe A., and Stanworth D.R. The use of synthetic gamma-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages. Immunol Lett 4 4 (1982) 215-221